• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Anti-TNF therapy for inflammatory bowel disease may induce skin lesions

byKenan Celtik, MSandSai Folmsbee
December 8, 2015
in Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. From a retrospective single center cohort study, 29% of patients taking anti-TNF therapy for inflammatory bowel disease developed skin manifestations, most often psoriasiform eczema and eczema.

2. Of those who developed skin manifestations, 10.6% stopped therapy because of the skin lesions, and most lesions resolved upon discontinuation of therapy.

Evidence Rating Level: 2 (Good)

Study Rundown: Disease-modifying biologics such as anti-tumor necrosis factor (TNF) antibodies have been effective in the treatment of some cancers, infections and autoimmune diseases, like inflammatory bowel disease (IBD). This study sought to understand the frequency and characteristics of patients who developed skin manifestations associated with treatment with anti-TNF therapy, as well as how it affected adherence to therapy. This study found that nearly one-third of patients with IBD treated with anti-TNF antibodies developed skin lesions within two years after starting treatment. Most often these skin lesions were psoriasiform eczema or eczema occurring on the extremities, face, trunk and flexural regions. Skin lesions caused about 1 in 10 patients to stop treatment. Patients who developed skin lesions were more likely to be female, develop new autoimmune markers (i.e., ANA and anti-dsDNA) after beginning therapy and be younger at the time of IBD diagnosis or therapy initiation. Skin lesions appeared not to be related to cumulative dose of therapy taken per year. Bacterial super infections occurred in nearly a quarter of skin lesions. Of those who developed skin lesions from anti-TNF therapy, more than half required topical treatment, and one-third required systemic drugs. The major limitations of this study included its retrospective nature, the lack of matched-controls, uneven baseline patient characteristics and limited generalizability due to its single institution experience. Overall, it is clear that skin lesions may be an important consideration in the utilization of anti-TNF therapies in IBD.

Click to read the study published today in the Annals of Internal Medicine

Relevant Reading: Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy

In-Depth [retrospective cohort]: This single-center cohort consisted of 917 European patients with IBD diagnosed at median age 24 years who began anti-TNF (infliximab) therapy at median age 36 years. The median follow-up after infliximab initiation was 3.5 years. Skin lesions developed in 264 (29%) of patients at a median of 11.6 years after diagnosis and 1.9 years after infliximab initiation. Those who developed skin lesions were younger at diagnosis (median 22 years vs. 25 years) and initiation of infliximab (median 32 years vs. 37 years). Of the 604 patients who received maintenance therapy, 230 (38%) developed skin manifestations during follow up, of which 178 were first noted during the maintenance therapy period. The cumulative dose and trough levels were similar between patients with and without skin lesions. The most common type of skin lesions were psoriasiform eczema (30.6%) and eczema (23.5%), but xerosis cutis (10.6%), palmoplantar pustulosis (5.3%), bacterial folliculitis (4.5%) and psoriasis (3.8%) also occurred in significant numbers. Twenty-eight patients (10.6%) stopped therapy because their lesions were intolerable due to location (i.e., face and scalp were less tolerable), itching or pain, and 17 had resolution within a median of 3 months of discontinuation. 

RELATED REPORTS

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

#VisualAbstract: Dual therapy with infliximab and IVIG in children with multi-system inflammatory syndrome

Image: CC/Wiki

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: IBDInfliximabTNF
Previous Post

2 Minute Medicine Rewind December 7, 2015

Next Post

Majority of adolescents’ physical activity obtained at school

RelatedReports

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa
StudyGraphics

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

December 23, 2021
#VisualAbstract: Dual therapy with infliximab and IVIG in children with multi-system inflammatory syndrome
StudyGraphics

#VisualAbstract: Dual therapy with infliximab and IVIG in children with multi-system inflammatory syndrome

December 12, 2021
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is associated with lower COVID-19 hospitalization and death rates compared to other treatments

October 20, 2021
Next Post
Majority of adolescents’ physical activity obtained at school

Majority of adolescents’ physical activity obtained at school

Weekly GLP-1 receptor agonists may reduce HbA1c and fasting glucose

Weekly GLP-1 receptor agonists may reduce HbA1c and fasting glucose

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The RE-ALIGN trial: Dabigatran vs. warfarin for mechanical heart valves [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Sleep
  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.